Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Replication timing alterations in leukemia affect clinically relevant chromosome domains.

Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, Eaves CJ, Gilbert DM.

Blood Adv. 2019 Nov 12;3(21):3201-3213. doi: 10.1182/bloodadvances.2019000641.

PMID:
31698451
2.

Revisiting NTRKs as an emerging oncogene in hematological malignancies.

Joshi SK, Davare MA, Druker BJ, Tognon CE.

Leukemia. 2019 Sep 24. doi: 10.1038/s41375-019-0576-8. [Epub ahead of print] Review.

PMID:
31551508
3.

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW.

Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19.

PMID:
31543464
4.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
5.

Challenges and approaches to implementing master/basket trials in oncology.

Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR.

Blood Adv. 2019 Jul 23;3(14):2237-2243. doi: 10.1182/bloodadvances.2019031229.

6.

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.

Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM.

Cancer Res. 2019 Sep 15;79(18):4744-4753. doi: 10.1158/0008-5472.CAN-19-1236. Epub 2019 Jul 16.

PMID:
31311809
7.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

PMID:
31209280
8.

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.

Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, Fan G, Raess PW, Druker BJ, Traer E.

Am J Hematol. 2019 Aug;94(8):913-920. doi: 10.1002/ajh.25517. Epub 2019 Jun 21.

9.

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.

Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.

PMID:
31048320
10.

Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Mar 29;8. pii: e47174. doi: 10.7554/eLife.47174.

11.

FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.

Elife. 2019 Feb 5;8. pii: e40033. doi: 10.7554/eLife.40033. Erratum in: Elife. 2019 Mar 29;8:.

12.

Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.

Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR.

Blood. 2019 Apr 4;133(14):1597-1606. doi: 10.1182/blood-2018-10-881557. Epub 2019 Jan 28.

PMID:
30692122
13.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

14.

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.

Leuk Res. 2019 Feb;77:42-50. doi: 10.1016/j.leukres.2018.11.010. Epub 2019 Jan 7.

15.

Reply to N. Cerveira et al.

Berman E, Druker BJ, Burwick R.

J Clin Oncol. 2019 Jan 1;37(1):90-91. doi: 10.1200/JCO.18.01004. Epub 2018 Nov 13. No abstract available.

PMID:
30422739
16.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

17.

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar R, Gilheeney SW, DeCarvalo A, Mikkelson T, Van Meir EG, Ladanyi M, Druker BJ.

Clin Cancer Res. 2018 Dec 15;24(24):6471-6482. doi: 10.1158/1078-0432.CCR-18-1052. Epub 2018 Aug 31.

PMID:
30171048
18.

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.

Leukemia. 2018 Sep;32(9):2025-2028. doi: 10.1038/s41375-018-0225-7. Epub 2018 Aug 6. No abstract available.

19.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.

Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15.

20.

Reply to D.M. Ross et al and V. Florou et al.

Berman E, Druker BJ, Burwick R.

J Clin Oncol. 2018 Sep 1;36(25):2660-2661. doi: 10.1200/JCO.2018.79.1806. Epub 2018 May 31. No abstract available.

PMID:
29851547
21.

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A.

Leukemia. 2018 Nov;32(11):2374-2387. doi: 10.1038/s41375-018-0112-2. Epub 2018 Mar 29.

22.

Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK 5th.

Haematologica. 2018 Aug;103(8):e351-e355. doi: 10.3324/haematol.2018.190926. Epub 2018 Mar 22. No abstract available.

23.

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.

Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F.

Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.

24.

Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy.

Berman E, Druker BJ, Burwick R.

J Clin Oncol. 2018 Apr 20;36(12):1250-1256. doi: 10.1200/JCO.2017.77.2574. Epub 2018 Feb 15. Review. No abstract available.

PMID:
29447062
25.

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.

Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ Jr, Druker BJ, Tyner JW, Gill PS.

Blood Adv. 2017 Aug 28;1(20):1635-1644. doi: 10.1182/bloodadvances.2017005694. eCollection 2017 Sep 12.

26.

A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.

Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T.

Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28. No abstract available.

27.

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.

Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, Clark RE, Mitra S, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL, Helgason GV.

J Natl Cancer Inst. 2018 May 1;110(5):467-478. doi: 10.1093/jnci/djx236.

28.

CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.

Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16.

29.

Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.

Degnin M, Agarwal A, Tarlock K, Meshinchi S, Druker BJ, Tognon CE.

J Pediatr Hematol Oncol. 2017 Oct;39(7):e359-e366. doi: 10.1097/MPH.0000000000000946.

30.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

31.

Recurrent cyclin D2 mutations in myeloid neoplasms.

Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW.

Leukemia. 2017 Sep;31(9):2005-2008. doi: 10.1038/leu.2017.195. Epub 2017 Jun 20. No abstract available.

32.

Understanding cancer from the stem cells up.

Eide CA, Druker BJ.

Nat Med. 2017 Jun 6;23(6):656-657. doi: 10.1038/nm.4353. No abstract available.

PMID:
28586338
33.

Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.

Sasaki T, Rivera-Mulia JC, Vera D, Zimmerman J, Das S, Padget M, Nakamichi N, Chang BH, Tyner J, Druker BJ, Weng AP, Civin CI, Eaves CJ, Gilbert DM.

Exp Hematol. 2017 Jul;51:71-82.e3. doi: 10.1016/j.exphem.2017.04.004. Epub 2017 Apr 19.

34.

Peter C. Nowell (1928-2016).

Reed JC, Druker BJ.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4569-4570. doi: 10.1073/pnas.1705526114. Epub 2017 Apr 17. No abstract available.

35.

Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.

Henderson JJ, Wagner JP, Hofmann NE, Eide CA, Cho YJ, Druker BJ, Davare MA.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26553. Epub 2017 Apr 14.

PMID:
28409891
36.

Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy.

Burwick RM, Kuo K, Brewer D, Druker BJ.

Obstet Gynecol. 2017 May;129(5):831-834. doi: 10.1097/AOG.0000000000001972.

PMID:
28383372
37.

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A.

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

38.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

39.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

40.

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ.

Cancer Res. 2016 Nov 15;76(22):6471-6482. doi: 10.1158/0008-5472.CAN-15-3569. Epub 2016 Sep 26.

41.

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS.

Cancer Lett. 2016 Dec 28;383(2):220-229. doi: 10.1016/j.canlet.2016.09.025. Epub 2016 Oct 5.

PMID:
27720778
42.

Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.

Raess PW, Cascio MJ, Fan G, Press R, Druker BJ, Brewer D, Spurgeon SE.

Am J Hematol. 2017 Jan;92(1):E6-E8. doi: 10.1002/ajh.24586. Epub 2016 Nov 18. No abstract available.

43.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH.

Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.

PMID:
27582059
44.

Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting.

Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ.

Sci Rep. 2016 Jun 20;6:28163. doi: 10.1038/srep28163.

45.

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

Watanabe-Smith K, Tognon C, Tyner JW, Meijerink JP, Druker BJ, Agarwal A.

Leukemia. 2016 Sep;30(9):1950-3. doi: 10.1038/leu.2016.95. Epub 2016 Apr 27. No abstract available.

46.

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.

Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ.

Cureus. 2015 Dec 17;7(12):e414. doi: 10.7759/cureus.414.

47.

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.

de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, da Silva Souza Duarte A, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F.

Oncotarget. 2016 Feb 9;7(6):6948-59. doi: 10.18632/oncotarget.6851.

48.

Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.

Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, Gray NS, Druker BJ, Tyner JW.

Cancer Res. 2016 Jan 1;76(1):127-38. doi: 10.1158/0008-5472.CAN-15-0817. Epub 2015 Dec 17.

49.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16.

50.

Age-related mutations and chronic myelomonocytic leukemia.

Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, O'Hare T, Deininger MW.

Leukemia. 2016 Apr;30(4):906-13. doi: 10.1038/leu.2015.337. Epub 2015 Dec 9.

Supplemental Content

Loading ...
Support Center